It is responsible for research, prevention, diagnosis and treatment of diseases using radiopharmaceuticals. Radiopharmaceuticals are molecules that incorporate a small amount of radiation that, in addition to leaving a radioactive trace during the time necessary to perform the medical examination. They have another important quality since they can be directed towards a specific tissue or organ. Currently there is a large number of radiopharmaceuticals marketed and there is an important advance in research in the development of new compounds.
The Nuclear Medicine Service of the Hospital Quirónsalud Torrevieja, in addition to having the most advanced equipment in its area such as the PET-CT ─ with the capacity to detect a very small tumor, with a high sensitivity and a resolution of less than 5 mm─. or the Metabolic Therapy Unit ─with 4 hospitalization rooms under radiological protection regime cuenta, has a medical team with extensive experience with more than 10 years of PET studies (not only with FDG but with other PET radiopharmaceuticals) and in metabolic therapy being pioneers in the implantation in Spain of some of these therapeutic modalities. Our PET-CT images are used for radiotherapy planning, since specific equipment is available to determine treatment volumes.
The Nuclear Medicine Service is part of the Oncology Platform and actively collaborates in its oncological interdisciplinary programs such as the Selective Biopsy of the Sentinel Ganglion, the Surgery.
Radioguided, Radiometabolic Treatment of tumors or Isolated Perfusion of Extremity with TNF and melphalan.